US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Lucid Diagnostics Inc.
Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry
December 08, 2022
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
PAVM
PAVMZ
Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research
December 01, 2022
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
PAVM
PAVMZ
Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results
November 14, 2022
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
PAVM
PAVMZ
Lucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer
November 09, 2022
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
PAVM
PAVMZ
Lucid Diagnostics to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum
November 10, 2022
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
PAVM
PAVMZ
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022
November 02, 2022
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
PAVM
PAVMZ
Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results
August 15, 2022
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
PAVM
Lucid Diagnostics Launches Stage II Lucid Test Center Expansion in California, Texas, Florida, and Ohio
August 11, 2022
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
PAVM
PAVMZ
Newly Published American Gastroenterological Association Clinical Practice Update Supports Esophageal Precancer Screening Using Lucid Diagnostics’ EsoGuard® and EsoCheck® Technologies
August 04, 2022
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
PAVM
PAVMZ
Lucid Diagnostics to Hold a Business Update Conference Call on August 15, 2022
August 01, 2022
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
Lucid Diagnostics’ Laboratory Executes Four New Participating Provider Agreements
August 02, 2022
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
Lucid Diagnostics Provides Business Update and Preliminary First Quarter 2022 Financial Results
May 11, 2022
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
PAVM
Lucid Diagnostics to Participate in the Canaccord 42nd Annual Growth Conference and the 7th Annual Needham Med Tech & Diagnostics 1x1 Conference
July 18, 2022
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
PAVM
PAVMZ
Lucid Diagnostics to Hold a Business Update Conference Call on May 11, 2022
April 25, 2022
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
PAVM
Lucid Diagnostics’ Laboratory Executes Participating Provider Agreement with MediNcrease Health Plans
May 09, 2022
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
PAVM
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results
March 28, 2022
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
Lucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination
April 04, 2022
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
PAVM
PAVmed Subsidiary Lucid Diagnostics Announces Launch of VA EsoGuard® Study
March 24, 2022
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
PAVM
Lucid Diagnostics to Participate in the Needham 21st Annual Healthcare Conference
March 30, 2022
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
PAVM
PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers
March 23, 2022
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
PAVM
PAVMZ
Lucid Diagnostics to Participate in a Fireside Chat at the BTIG MedTech Digital Health, Life Science, and Diagnostics Tools Conference
February 10, 2022
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
PAVM
PAVMZ
Lucid Diagnostics to Participate in a Fireside Chat at the 24th Annual Needham Virtual Growth Conference
January 06, 2022
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
PAVM
PAVMZ
PAVmed Subsidiary Lucid Diagnostics Launches EsoGuard Telemedicine Program in Partnership with UpScriptHealth
December 01, 2021
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
PAVM
PAVMZ
PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers
November 11, 2021
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
PAVM
PAVMZ
Lucid Diagnostics’ EsoGuard Esophageal DNA Test Wins “Diagnostics Innovation of the Year” Award
October 28, 2021
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
PAVM
PAVMZ
ADDING MULTIMEDIA Lucid Diagnostics Appoints Suman Verma MD, PhD as Chief Scientific Officer
October 21, 2021
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
PAVM
PAVMZ
Lucid Diagnostics Appoints Suman Verma MD, PhD as Chief Scientific Officer
October 21, 2021
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
PAVM
PAVMZ
Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering
October 18, 2021
From
Lucid Diagnostics Inc.
Via
Business Wire
Tickers
LUCD
PAVM
PAVMZ
